{"organizations": [], "uuid": "47bef4789af1d8f7e74739e1ca51334c0909f532", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ab-science-fy-operating-loss-down/brief-ab-science-fy-operating-loss-down-at-28-4-million-euros-idUSL8N1S76MQ", "country": "US", "domain_rank": 408, "title": "BRIEF-AB Science FY Operating Loss Down At 28.4 Million Euros", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-30T19:59:00.000+03:00", "replies_count": 0, "uuid": "47bef4789af1d8f7e74739e1ca51334c0909f532"}, "author": "", "url": "https://www.reuters.com/article/brief-ab-science-fy-operating-loss-down/brief-ab-science-fy-operating-loss-down-at-28-4-million-euros-idUSL8N1S76MQ", "ord_in_thread": 0, "title": "BRIEF-AB Science FY Operating Loss Down At 28.4 Million Euros", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 30, 2018 / 5:00 PM / Updated 7 minutes ago BRIEF-AB Science FY Operating Loss Down At 28.4 Million Euros Reuters Staff\nApril 30 (Reuters) - AB SCIENCE SA:\n* FY NET LOSS EUR 27.1 MILLION VERSUS LOSS OF EUR 27.7 MILLION YEAR AGO\n* AB SCIENCE REPORTS TODAY ITS ANNUAL FINANCIALS AS OF 31 DECEMBER 2017 AND PROVIDES AN UPDATE ON ITS ACTIVITIES\n* FY NET REVENUES EUR 1.7 MILLION VERSUS EUR 1.5 MILLION YEAR AGO\n* FY OPERATING LOSS EUR 28.4 MILLION VERSUS LOSS OF EUR 30.2 MILLION YEAR AGO\n* INTENDS TO LAUNCH BY END 2018 A PHASE 1/2 REFRACTORY ACUTE MYELOID LEUKEMIA STUDY WITH NEW MOLECULE\n* INTENDS TO LAUNCH A CONFIRMATORY PHASE 3 STUDY IN INDOLENT SYSTEMIC MASTOCYTOSIS\n* SUBJECT TO AVAILABILITY OF FINANCIAL RESOURCES, AIMS TO START IN 2018 PRECLINICAL STUDIES OF NEW MOLECULES Source text for Eikon: Further company coverage: (Gdynia Newsroom)", "external_links": [], "published": "2018-04-30T19:59:00.000+03:00", "crawled": "2018-04-30T20:10:36.023+03:00", "highlightTitle": ""}